ArQule, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
CTLTCatalent, Inc. 1.56%82.052.1%$228.74m
SAVACassava Sciences, Inc. 18.13%11.470.0%$208.15m
JAZZJazz Pharmaceuticals Plc 1.11%139.582.4%$169.45m
HZNPHorizon Therapeutics Plc 3.88%78.255.8%$167.25m
MRNSMarinus Pharmaceuticals, Inc. 4.21%11.157.8%$124.96m
CORTCorcept Therapeutics, Inc. 1.88%17.095.5%$120.14m
VRXValeant Pharmaceuticals International, Inc. 0.53%15.3014.1%$90.03m
BHCBausch Health Cos., Inc. 0.53%15.300.0%$61.37m
MYOKMyoKardia, Inc. 2.08%132.721.8%$59.58m
AMRNAmarin Corp. Plc 4.67%3.811.5%$56.78m
ARGXargenx SE 2.26%248.570.0%$56.59m
SAGESAGE Therapeutics, Inc. 3.26%60.828.6%$46.31m
GWPHGW Pharmaceuticals Plc 1.97%100.446.2%$39.53m
AXSMAxsome Therapeutics, Inc. 1.44%77.021.9%$39.11m
ICLRICON plc 2.30%183.144.3%$36.29m

Company Profile

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).